1 a 1 F F M F d 2 China is the most populous country in the world, with 1.3 illion people. Its spectacular economic growth during the ast 10 to 15 years was accompanied by an explosive evelopment in cardiovascular medicine. Just 1 of the areas n which this medical evolution occurred is a relatively ecent but substantial interest in hypertrophic cardiomyopthy (HC). Despite the presence in China of many public ealth problems that surpass HC (and other genetic heart iseases) in sheer magnitude, it is notable that this cardiac isease also became a focus of grant support and research. In 2004, in an ambitious epidemiologic echocardioraphic study involving 8,000 subjects,1 the prevalence of henotypically expressed HC in China was reported to be imilar to that in the United States; in other words, about :500.2 That figure translates into 1 million potential Chiese patients with HC, although (not unlike in the United tates and Europe) most of those patients are presently naware of their underlying disease, including some unnowingly at risk of sudden cardiac death.2 Recently, HC investigators from around the world were ersonally introduced to the Chinese experience with this isease by Professor Rutai Hui (Beijing), who was an inited faculty member during our Third International Sumit “Diagnosis and Management of Hypertrophic Cardioyopathy and Sudden Death Prevention: The First 50 ears” in Minneapolis, Minnesota, October 20 to 22, 2006. e were honored to have Dr. Hui present a lecture entitled Hypertrophic Cardiomyopathy in China,” in which he reorted on both clinical studies and laboratory investigations nto the molecular biologic state of HC in Chinese patients. t is evident, even at this relatively early stage, that HC is argely the same disease in China as it is in other parts of the orld with regard to phenotypic expression, clinical course, nd underlying genetic substrate. During his 3 days in Mineapolis, Dr. Hui had the opportunity to interact and share is experiences (and that of his colleagues) with other faclty (n 35) and attendees (n 200) at the HC Summit Figure 1). Coincidently, 1 week later, I had the opportunity to travel o China and participate in the Third Chinese Conference on ardiomyopathy in Nanjing at the invitation of Dr. Zinan hang, the conference organizer and an established invesigator with basic science and clinical programs focused on C. Later, together with Dr. Kirk Knowlton of the Univerity of California at San Diego, we visited Dr. Hui at FuWai ospital in downtown Beijing (Figure 2). FuWai is a naional (and international) referral center for cardiovascular isease, where Dr. Hui and his colleagues are following up